Current Atherosclerosis Reports

, Volume 6, Issue 6, pp 424–431 | Cite as

Inflammation, insulin resistance, and obesity

  • Patrizia Ferroni
  • Stefani Basili
  • Angela Falco
  • Giovanni Davì


Obesity, in particular visceral obesity, has strong associations with cardiovascular disease and is related to many factors that are constituents of the metabolic syndrome. Increasing evidence suggests that features of the metabolic syndrome, including visceral obesity, are associated with a low-grade inflammatory state. Indeed, visceral fat is a source of several molecules, such as leptin, adiponectin, tumor necrosis factor-α, and interleukin 6, that are collectively called adipokines. All of them may induce a proinflammatory state and oxidative damage, leading to initiation and progression of atherosclerosis. Reducedenergy diets might represent an effective and healthful approach for long-term weight loss in patients with metabolic syndrome by reducing the underlying inflammatory condition.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002, 105:2696–2698.PubMedCrossRefGoogle Scholar
  2. 2.
    Morris JN: Occupation and coronary heart disease. Arch Intern Med 1959, 104:903–907.PubMedGoogle Scholar
  3. 3.
    Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric-calculous disease. Am J Clin Nutr 1956, 4:20–34.PubMedGoogle Scholar
  4. 4.
    Larsson B, Svardsudd K, Welin L, et al.: Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ 1984, 288:1401–1404.PubMedGoogle Scholar
  5. 5.
    Lakka HM, Lakka TA, Tuomilehto J, Salonen JT: Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002, 23:706–713.PubMedCrossRefGoogle Scholar
  6. 6.
    Bengtsson G, Bjorkelund C, Lapidus L, Lissner L: Associations of serum lipid concentrations and obesity with mortality in women: 20 year follow up of participants in prospective population study in Gothenburg, Sweden. BMJ 1993, 307:1385–1388.PubMedCrossRefGoogle Scholar
  7. 7.
    Prineas RJ, Folsom AR, Kaye SA: Central adiposity and increased risk of coronary artery disease mortality in older women. Ann Epidemiol 1993, 3:35–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Larsson B, Bengtsson C, Bjorntorp P, et al.: Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Göteborg, Sweden. Am J Epidemiol 1992, 135:266–273.PubMedGoogle Scholar
  9. 9.
    Welborn TA, Dhaliwal SS, Bennett SA: Waist-hip ratio is the dominant risk factor predicting cardiovascular death in Australia. Med J Aust 2003, 179:580–585.PubMedGoogle Scholar
  10. 10.
    McGill HC Jr, McMahan CA, Herderick EE, et al., for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group: Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002, 105:2712–2718.PubMedCrossRefGoogle Scholar
  11. 11.
    Srinivasan SR, Bao W, Wattigney WA, Berenson GS: Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: The Bogalusa heart study. Metabolism 1996, 45:235–240.PubMedCrossRefGoogle Scholar
  12. 12.
    Wright CM, Parker L, Lamont D, Craft AW: Implications of childhood obesity for adult health: Findings from thousand families cohort study. BMJ 2001, 323:1280–1284.PubMedCrossRefGoogle Scholar
  13. 13.
    Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report.Circulation 2002, 106:3143–3421.Google Scholar
  14. 14.
    Marchesini G, Forlani G, Cerrelli F, et al.: WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabetes Med 2004, 21:383–387.CrossRefGoogle Scholar
  15. 15.
    Einhorn D, Reaven GM, Cobin RH, et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003, 9:237–252.PubMedGoogle Scholar
  16. 16.
    Grundy SM, Brewer HB, Cleeman JI, et al.: Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004, 109:433–438.PubMedCrossRefGoogle Scholar
  17. 17.
    Steppan CM, Lazar MA: The current biology of resistin. J Intern Med 2004, 255:439–447.PubMedCrossRefGoogle Scholar
  18. 18.
    Benoit SC, Clegg DJ, Seeley RJ, Woods SC: Insulin and leptin as adiposity signals. Recent Prog Horm Res 2004, 59:67–85.CrossRefGoogle Scholar
  19. 19.
    Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941–946.PubMedCrossRefGoogle Scholar
  20. 20.
    Yang WS, Lee WJ, Funahashi T, et al.: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001, 86:3815–3819.PubMedCrossRefGoogle Scholar
  21. 21.
    Guagnano MT, Romano M, Falco A, et al.: Leptin increase is associated with markers of the hemostatic system in obese healthy women. J Thromb Haemost 2003, 1:2330–2334.PubMedCrossRefGoogle Scholar
  22. 22.
    Guagnano MT, Manigrasso MR, Ballone E, et al.: Association between serum leptin levels and 24-hour blood pressure in obese women. Obes Res 2003, 11:549–555.PubMedCrossRefGoogle Scholar
  23. 23.
    Choi KM, Lee J, Lee KW, et al.: The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004, 150:715–718.PubMedCrossRefGoogle Scholar
  24. 24.
    Steinbaum SR: The metabolic syndrome: an emerging health epidemic in women. Prog Cardiovasc Dis 2004, 46:321–336.PubMedCrossRefGoogle Scholar
  25. 25.
    Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27:S53-S55.PubMedCrossRefGoogle Scholar
  26. 26.
    Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science 1993, 259:87–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Kern PA, Saghizadeh M, Ong JM, et al.: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111–2119.PubMedGoogle Scholar
  28. 28.
    Dandona P, Weinstock R, Thusu K, et al.: Tumor necrosis factoralpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998, 83:2907–2910.PubMedCrossRefGoogle Scholar
  29. 29.
    Hak AE, Stehouwer CD, Bots ML, et al.: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical arteriosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999, 19:1986–1991.PubMedGoogle Scholar
  30. 30.
    Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.PubMedCrossRefGoogle Scholar
  31. 31.
    Festa A, D’Agostino RJ, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42–47.PubMedGoogle Scholar
  32. 32.
    Campos SP, Baumann H: Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 1992, 12:1789–1797.PubMedGoogle Scholar
  33. 33.
    Mohamed-Ali V, Goodrick S, Rawesh A, et al.: Subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-alpha in vivo. J Clin Endocrinol Metab 1997, 82:4196–4200.PubMedCrossRefGoogle Scholar
  34. 34.
    Yudkin JS: Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obesity 2003, 27:S25-S28.CrossRefGoogle Scholar
  35. 35.
    Kubaszek A, Pihlajamaki J, Komarovski V, et al.: Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2003, 52:1872–1876.PubMedCrossRefGoogle Scholar
  36. 36.
    Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obesity 2003, 27:S53-S55.CrossRefGoogle Scholar
  38. 38.
    Tong Q, Dalgin G, Xu H, et al.: Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 2000, 290:134–138.PubMedCrossRefGoogle Scholar
  39. 39.
    Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830.PubMedCrossRefGoogle Scholar
  40. 40.
    Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.PubMedCrossRefGoogle Scholar
  41. 41.
    Wellen KE, Hotamisligil GS: Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112:1785–1788.PubMedCrossRefGoogle Scholar
  42. 42.
    Romano M, Guagnano MT, Pacini G, et al.: Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 2003, 88:5321–5326.PubMedCrossRefGoogle Scholar
  43. 43.
    Davi G, Falco A, Patrono C: Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004, 128:149–163.PubMedCrossRefGoogle Scholar
  44. 44.
    Roberts LJ II, Morrow JD: Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci 2002, 59:808–820.PubMedCrossRefGoogle Scholar
  45. 45.
    Keaney JF, Larson MG, Vasan RS, et al.: Obesity and systemic oxidant stress: clinical correlates of oxidative stress in the Framingham Study. Arteroscler Thromb Vasc Biol 2003, 23:434–439.CrossRefGoogle Scholar
  46. 46.
    Davi G, Guagnano MT, Ciabattoni G, et al.: Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002, 288:2008–2014.PubMedCrossRefGoogle Scholar
  47. 47.
    Urakawa H, Katsuki A, Sumida Y, et al.: Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 2003, 88:4673–4676.PubMedCrossRefGoogle Scholar
  48. 48.
    Esposito K, Pontillo A, Di Palo C, et al.: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. A randomized trial. JAMA 2003, 289:1799–1804.PubMedCrossRefGoogle Scholar
  49. 49.
    You T, Berman DM, Ryan AS, Nicklas BJ: Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab 2004, 89:1739–1746.PubMedCrossRefGoogle Scholar
  50. 50.
    Nicklas BJ, Ambrosius W, Messier SP, et al.: Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr 2004, 79:544–551.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Patrizia Ferroni
  • Stefani Basili
  • Angela Falco
  • Giovanni Davì
    • 1
  1. 1.Center of Excellence on AgingVia colle dell’AraChietiItaly

Personalised recommendations